Antiviral Activity of Naringenin Against Equine Alphaherpesvirus Type 8 In Vitro.
- 1College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030600, China.
- 2College of Agriculture and Biology, Liaocheng University, Liaocheng 252000, China.
Abstract
Equine alphaherpesvirus type 8 (EHV-8) is an economically significant emerging pathogen responsible for severe respiratory disease, reproductive failure, and neurological disorders in equids worldwide. The escalating prevalence of EHV-8 in large-scale donkey farming operations, particularly in China, has resulted in substantial economic losses; however, no licensed antiviral agents or prophylactic vaccines are currently available. In the present study, we evaluated the anti-EHV-8 activity of naringenin in susceptible cells and comprehensively explored the underlying molecular mechanisms. Our results demonstrated that naringenin markedly inhibited EHV-8 infection in RK-13 and NBL-6 cells in a dose-dependent manner. Moreover, naringenin blocked the replication of EHV-8 via HO-1 (heme oxygenase-1)-mediated type I interferon (IFN) response. Collectively, our findings indicate that naringenin may serve as a promising therapeutic drug for the treatment of EHV-8 infection.
Related
- Antiviral activity of Rumex crispus extract and its bioactive constituent emodin against human coronavirus OC43
- Trifluoperazine exhibits broad-spectrum antiviral activity against arboviruses
- Multivalent antiviral conjugates enhance activity against Influenza via cross-linking viruses
- Antiviral activity of HSP90 inhibitors against Mumps virus and related paramyxoviruses
- Host-targeted repurposed diltiazem enhances the antiviral activity of direct acting antivirals against Influenza A virus and SARS-CoV-2
BibTeX
@article{you2026antiviral,
title = {{Antiviral Activity of Naringenin Against Equine Alphaherpesvirus Type 8 In Vitro.}},
author = {Anrong You and Rongze Yang and Wei Wang and Enxin Li and Muhammad Zahoor Khan and Liangliang Li and Changfa Wang and Tongtong Wang and Juan Zhao},
journal = {Veterinary sciences},
year = {2026},
month = sep,
doi = {10.3390/vetsci13101022},
url = {https://europepmc.org/article/MED/42944118},
note = {CC BY},
}
RIS
TY - JOUR
TI - Antiviral Activity of Naringenin Against Equine Alphaherpesvirus Type 8 In Vitro.
AU - Anrong You
AU - Rongze Yang
AU - Wei Wang
AU - Enxin Li
AU - Muhammad Zahoor Khan
AU - Liangliang Li
AU - Changfa Wang
AU - Tongtong Wang
AU - Juan Zhao
PY - 2026
DA - 2026/09/27
JO - Veterinary sciences
DO - 10.3390/vetsci13101022
UR - https://europepmc.org/article/MED/42944118
AB - Equine alphaherpesvirus type 8 (EHV-8) is an economically significant emerging pathogen responsible for severe respiratory disease, reproductive failure, and neurological disorders in equids worldwide. The escalating prevalence of EHV-8 in large-scale donkey farming operations, particularly in China, has resulted in substantial economic losses; however, no licensed antiviral agents or prophylactic vaccines are currently available. In the present study, we evaluated the anti-EHV-8 activity of naringenin in susceptible cells and comprehensively explored the underlying molecular mechanisms. Our results demonstrated that naringenin markedly inhibited EHV-8 infection in RK-13 and NBL-6 cells in a dose-dependent manner. Moreover, naringenin blocked the replication of EHV-8 via HO-1 (heme oxygenase-1)-mediated type I interferon (IFN) response. Collectively, our findings indicate that naringenin may serve as a promising therapeutic drug for the treatment of EHV-8 infection.
SN - 2306-7381
ER -